



## Company Overview

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

## Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million

Oct 31 2018, 8:00 PM EDT

## Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oct 31 2018, 6:56 PM EDT

## Stock Overview

Symbol	OASM	Oasmia Pharmaceutical AB
Exchange	Nasdaq	Anders Blom
Shares OS	179,309,596	Executive Vice President
Market Cap	\$607.86M	Vallongatan 1
Last Price	\$3.39	752 28, Uppsala
52-Week Range	\$0.85 - \$5.70	Sweden
		T: +46 18 50 54 40
		<a href="mailto:anders.blom@oasmia.com">anders.blom@oasmia.com</a>

12/17/2018 04:00 PM EST

## Management Team

### Julian Aleksov

Executive Vice Chairman of the Board

### Anders Blom

Executive Vice President & Acting Chief Financial Officer

### Mikael Asp

Chief Executive Officer

## Oasmia Pharmaceutical AB

Vallongatan 1  
Uppsala 752 28  
Sweden

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.